Keyphrases
Specific T Cells
57%
Programmed Death-ligand 1 (PD-L1)
51%
Cancer Patients
23%
In Cancer
20%
Vaccination
20%
Immune Response
19%
Peptide Vaccination
19%
Immune Modulatory Vaccine
19%
CD8+ T Cells
18%
Calreticulin
18%
Arginase-1 (Arg-1)
18%
CD4+ T Cells
15%
Tumor Microenvironment
14%
Metastatic Melanoma
14%
Exon 9
12%
Indoleamine 2,3-dioxygenase 1 (IDO1)
12%
PD-L2
12%
Multiple Myeloma
12%
Cancer Cells
11%
Epitope
10%
Immunogenicity
10%
Autoreactive T Cells
9%
T Cells
9%
T Cell Response
9%
Cell-based
8%
Stable Disease
8%
Healthy Individuals
8%
Effector T Cells
8%
Myeloproliferative Neoplasms
8%
Tumor-specific
8%
Tumor
7%
CD4+ T
7%
CD4 T Cells
7%
Therapeutic Vaccination
7%
Therapeutic Vaccine
7%
Cytotoxic T Lymphocytes
7%
Tumor Cells
7%
Immunosuppressive Microenvironment
7%
Dendritic Cell Vaccine
7%
Memory T Cells
7%
T Cell Epitope
6%
Peripheral Blood
6%
MHC Class II
6%
HLA-A2
6%
Cancer Immune Therapy
6%
Human Immune System
6%
Human Leukocyte Antigen
6%
Adaptive Immune Response
6%
Cutaneous T-cell Lymphoma
6%
Healthy Donors
6%
Immunology and Microbiology
T Cell
100%
Programmed Death-Ligand 1
44%
Vaccination Policy
40%
Cytotoxic T-Cell
30%
T-Helper Cell
28%
Vaccine Efficacy
27%
Immune Response
22%
Epitope
22%
Cancer Cell
20%
Dendritic Cell
18%
Programmed Death 1 Ligand 1
14%
Immunotherapy
13%
Regulatory T Cell
13%
Cytotoxic T Cell
13%
Immunosuppressive Drug
12%
Indoleamine 2,3-dioxygenase
12%
Calreticulin
12%
Immunogenicity
11%
CD8
9%
Memory T Cell
8%
Cancer Vaccine
7%
MHC Class II
7%
Immunocompetent Cell
6%
Tumor Cell
6%
Human Leukocyte Antigen
6%
Adaptive Immune System
6%
Myeloid
6%
Cyclophosphamide
6%
Co-Stimulation
6%
MHC Class I
6%
Antigen Presentation
6%
Staphylococcus Aureus
6%
Immunity
6%
Interleukin 2
6%
Exon
6%
Galectin 3
6%
Nivolumab
6%
Immunoglobulin Heavy Chain
6%
Multiple Myeloma
6%
CCL22
6%
CD4
5%
Normal Human
5%
Tumor Necrosis Factor
5%
Peripheral Blood Mononuclear Cell
5%
Medicine and Dentistry
T Cell
28%
Cytotoxic T-Cell
17%
Metastatic Melanoma
14%
Malignant Neoplasm
13%
Neoplasm
12%
Arginase 1
12%
Calreticulin
12%
Programmed Death-Ligand 1
12%
Immunotherapy
11%
T-Helper Cell
10%
Immune Response
10%
Specific Tumor
8%
T-Cell Response
7%
Nodular Melanoma
6%
Adaptive Immunity
6%
Indoleamine 2,3 Dioxygenase
6%
Myeloproliferative Neoplasm
6%
Exon
6%
Cancer Immunization
6%
Nivolumab
6%
Myeloid Cell
6%
Interleukin 2
6%
Dendritic Cell
6%
Immunity
6%
Recurrent Disease
6%
Multiple Myeloma
6%
Phase II Trials
6%
Tumor Regression
6%
Cyclophosphamide
6%
